丙戍酸镁合并利培酮治疗精神分裂症血药浓度变化及临床疗效

目的探讨丙戍酸镁合并利培酮治疗精神分裂症对利培酮血药浓度的影响及临床疗效。方法 60例精神分裂症患者随机分为研究组与对照组各30例,研究组丙戍酸镁合并利培酮治疗;对照组单一利培酮治疗。于治疗开始,治疗2、4、6、8、12周对两组患者进行利培酮血药浓度检测,同时使用阳性与阴性评定量表(PANSS)进行临床疗效评定并进行组间组内对比。结果研究组各周利培酮血药浓度均高于对照组(t=2.09,2.96,7.02,5.04,6.12;P0.05或P0.01),研究组(t=7.24,10.88,18.68,24.08,27.42;P0.01)和对照组(t=4.03,8.76,13.73,21.05,25.85;P0.01)临床疗效与治疗开始比较均有显著疗效,但研究组各周优于对照组(t=4.86,3.52,10.17,10.94,6.12;P0.01)。结论丙戍酸镁合用利培酮治疗精神分裂症能进一步提高疗效,与丙戍酸镁特殊作用机制有关。

Change of Blood Drug Concentration and Effect Analysis by Risperidone and Magnesium Valproate in Patients with Schizophrenia

Objective To investigate change of blood drug concentration and effect in patients with schizophrenia by risperidone and magnesium valproate .Methods 60 patients with schizophrenia were randomly divided into observation group （ 30 cases ） and control group（30 cases）.The observation group applied risperidone and magnesium valproate ,the control group applied risperidone .The blood drug concentration of risperidone and clinical effect （PANSS scores） were observed in different time （2 weeks,4 weeks,,6 weeks,8 weeks,12 weeks）in two groups.Results Blood drug concentration of risperidone were higher in the observation group than in the control group（t=2.09,2.96,7.02,5.04,6.12;P〈0.05 or P〈0.01）.The clinical effect were better after treatment in observation group （t=7.24,10.88,18.68,24.08,27.42;P〈0.01）and control group（t=4.03,8.76,13.73,21.05,25.85;P〈0.01）.But the effect were higher in the observation group than in the control group （t=4.86,3.52,10.17,10.94,6.12;P〈0.01）.Conclusion Risperidone and magnesium valproate can improve effect in patients with schizophrenia .The mechanism is correlated with magnesium valproate＇s special effect.